Sinotherapeutics Inc. (SHA:688247)
China
· Delayed Price · Currency is CNY 9.69
-0.05 (-0.51%)
Mar 9, 2026, 4:00 PM EDT
Sinotherapeutics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Net Income | - | 127.7 | 61.07 | 92.93 | 134.92 | Upgrade
|
| Depreciation & Amortization | - | 18.36 | 23.27 | 26.43 | 26.94 | Upgrade
|
| Other Amortization | - | 7.09 | 0.78 | 1.54 | 1.84 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | -0.08 | -0.16 | 0.02 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | -1.03 | 1.72 | -2.55 | 1.04 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -11 | -9.61 | -20.79 | -3.9 | Upgrade
|
| Stock-Based Compensation | - | - | - | - | 7.94 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 3.93 | 0.81 | 1.43 | -0.29 | Upgrade
|
| Other Operating Activities | - | -2.06 | -1.22 | -5.31 | 4.25 | Upgrade
|
| Change in Accounts Receivable | - | -25.28 | -2.18 | -42.77 | -6.61 | Upgrade
|
| Change in Inventory | - | -16.46 | -56.47 | 13.83 | -0.05 | Upgrade
|
| Change in Accounts Payable | - | 17.53 | -4.11 | 12.6 | -52.23 | Upgrade
|
| Change in Other Net Operating Assets | - | 16.63 | -3.03 | -3.5 | 33.69 | Upgrade
|
| Operating Cash Flow | - | 130.23 | 12.96 | 73.18 | 145.77 | Upgrade
|
| Operating Cash Flow Growth | - | 905.01% | -82.29% | -49.80% | -30.60% | Upgrade
|
| Capital Expenditures | - | -94.93 | -38.96 | -176.34 | -16.01 | Upgrade
|
| Cash Acquisitions | - | - | - | -10.85 | - | Upgrade
|
| Investment in Securities | - | -399.89 | -84.41 | -20 | -52.6 | Upgrade
|
| Other Investing Activities | - | 10.98 | 15.79 | 6.88 | 4.38 | Upgrade
|
| Investing Cash Flow | - | -483.84 | -107.57 | -200.31 | -64.23 | Upgrade
|
| Long-Term Debt Repaid | - | -0.07 | -0.16 | -0.92 | -0.93 | Upgrade
|
| Net Debt Issued (Repaid) | - | -0.07 | -0.16 | -0.92 | -0.93 | Upgrade
|
| Issuance of Common Stock | - | - | - | 389.93 | - | Upgrade
|
| Repurchase of Common Stock | - | -36.15 | - | - | - | Upgrade
|
| Common Dividends Paid | - | -27.88 | -28.11 | - | - | Upgrade
|
| Other Financing Activities | - | - | - | -13.36 | - | Upgrade
|
| Financing Cash Flow | - | -64.09 | -28.27 | 375.65 | -0.93 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 1.71 | 1.52 | 2.97 | -2.9 | Upgrade
|
| Net Cash Flow | - | -416 | -121.36 | 251.5 | 77.71 | Upgrade
|
| Free Cash Flow | - | 35.3 | -26 | -103.15 | 129.77 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | -24.42% | Upgrade
|
| Free Cash Flow Margin | - | 6.90% | -8.67% | -41.67% | 41.13% | Upgrade
|
| Free Cash Flow Per Share | - | 0.08 | -0.06 | -0.24 | 0.32 | Upgrade
|
| Cash Income Tax Paid | - | 5.13 | 1.28 | 9.17 | 1.1 | Upgrade
|
| Levered Free Cash Flow | - | -22.06 | -42.85 | -150.44 | 30.86 | Upgrade
|
| Unlevered Free Cash Flow | - | -22.06 | -42.82 | -150.31 | 31.01 | Upgrade
|
| Change in Working Capital | - | -12.76 | -63.78 | -20.34 | -26.98 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.